ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,144Medicare Part D Prescriptions Filled, Including Refills

Rank: 207 out of 783

$657K Total Retail Price of All Prescriptions

Rank: 162 out of 783

537 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
31% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

2% of this provider’s 537 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

13% of this provider’s 537 patients filled at least one prescription for a schedule three drug, compared to an average of 16%.

Risky Drugs to Seniors

1% of this provider’s 8,119 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$72 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
HYDROCODONE-ACETAMINOPHEN 342 315 S3 1 2
LEVOTHYROXINE SODIUM 323 273 2 1
PRAVASTATIN SODIUM 316 288 3 14
SIMVASTATIN 277 260 4 3
OMEPRAZOLE 261 233 5 6
LISINOPRIL 208 176 6 4
WARFARIN SODIUM 206 197 7 10
FUROSEMIDE 180 173 8 7
METFORMIN HCL 166 128 9 8
AMLODIPINE BESYLATE 157 139 10 5
TRAMADOL HCL 139 112 11 20
METOPROLOL SUCCINATE 133 116 12 13
HYDROCHLOROTHIAZIDE 131 120 13 12
TRAZODONE HCL 131 112 13 39
TAMSULOSIN HCL 127 115 15 26
CARVEDILOL 121 115 16 21
ATORVASTATIN CALCIUM 118 100 17 11
LOSARTAN POTASSIUM 115 105 18 18
ALENDRONATE SODIUM 113 87 19 25
GABAPENTIN 111 98 20 15
METOPROLOL TARTRATE 111 111 20 9
LISINOPRIL-HYDROCHLOROTHIAZIDE 108 92 22 33
ATENOLOL 105 98 23 17
CLOPIDOGREL 98 96 24 29
DONEPEZIL HCL 96 96 25 24
CYMBALTA 89 73 26 35
SERTRALINE HCL 89 88 26 22
NAMENDA 87 87 28 32
GLIMEPIRIDE 83 74 29 34
LOSARTAN-HYDROCHLOROTHIAZIDE 78 78 30 53
PAROXETINE HCL 78 64 30 69
DIOVAN 78 62 30 49
CRESTOR 78 64 30 27
PLAVIX 76 72 34 51
CITALOPRAM HBR 72 68 35 19
FENOFIBRATE 70 51 36 66
CELEBREX 70 70 36 93
EVISTA 70 70 36 92
POTASSIUM CHLORIDE 67 63 39 16
SPIRIVA 65 58 40 59
AVODART 63 63 41 263
ENALAPRIL MALEATE 62 48 42 68
ALLOPURINOL 62 62 42 31
NEXIUM 61 56 44 28
FLUOXETINE HCL 58 56 45 45
AMITRIPTYLINE HCL 56 53 R 46 77
DIOVAN HCT 55 49 47 94
ADVAIR DISKUS 55 33 47 50
FLUTICASONE PROPIONATE 55 49 47 46
ZOLPIDEM TARTRATE 54 54 50 23
FENTANYL 52 42 S2 51 65
BYSTOLIC 51 41 52 99
KLOR-CON M20 50 50 53 48
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 7, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.